NCT04559854: MAC

Mindful After Cancer: A Mindfulness-based Therapy Intervention for Sexual Health After Cancer

Completed NA Results posted Last updated 25 June 2025

What this trial tests

NA trial testing Mindful After Cancer in Breast Cancer in 22 participants. Completed in 5 October 2020.

Timeline

1 July 2019

Primary endpoint
1 October 2020

5 October 2020

Quick facts

Lead sponsor	Oregon State University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	supportive care
Enrollment	22
Start date	1 July 2019
Primary completion	1 October 2020
Estimated completion	5 October 2020
Sites	1 location across United States

Drugs / interventions tested

• Mindful After Cancer

Conditions studied

• Breast Cancer — all drugs for Breast Cancer →
• Gynecologic Cancer — all drugs for Gynecologic Cancer →

Sponsor

Oregon State University

Who can join

Adults 18 to 89, female only, with Breast Cancer or Gynecologic Cancer. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Feasibility/ Enrollment in the Study Primary · Baseline (T1)

Percentage of participants enrolled of those eligible

Group	Value	95% CI
Mindful After Cancer	78.6

Feasibility/ Retention in the Study Primary · 1 month post-intervention (T2)

Number and percentage of participants completing all assessments

Group	Value	95% CI
Mindful After Cancer	22

Feasibility/ Retention in the Intervention Primary · 1 month post-intervention (T2)

Number and percentage attending at least 6 of 8 sessions

Group	Value	95% CI
Mindful After Cancer	18

Acceptability of the Intervention Primary · 1 month post-intervention (T2)

Endorsement of 10 items characterizing acceptability of the intervention (e.g., the program met my expectations). Range 10-100. Higher score indicates better acceptability.

Group	Value	95% CI
Mindful After Cancer	75.5	± 22.9

Change From Baseline Interest in Sexual Activity at 1 Month Secondary · Baseline (T1) and 1 month post-intervention (T2)

PROMIS Sexual Function and Satisfaction 2.0. 2 items. Range 2-10. Higher score indicates more interest in sexual activity.

T1 Mean, SD

Group	Value	95% CI
Mindful After Cancer	4.4	± 1.4

T2 Mean, SD

Group	Value	95% CI
Mindful After Cancer	5.0	± 1.7

Change From Baseline Satisfaction With Sex Life at 1 Month Secondary · Baseline (T1) and 1 month post-intervention (T2)

New Sexual Satisfaction Scale- Short Form (NSSS-S). 12 items. Range 12-60. Higher score indicates more sexual satisfaction.

T1 Mean, SD

Group	Value	95% CI
Mindful After Cancer	35	± 6.8

T2 Mean, SD

Group	Value	95% CI
Mindful After Cancer	37.3	± 7.4

Change From Baseline Self-efficacy at 1 Month Secondary · Baseline (T1) and 1 month post-intervention (T2)

Self-efficacy for Managing Chronic Disease Scale (adapted). 6 items. Range 6-60. Higher score indicates better self-efficacy for managing sexual health after cancer.

Group	Value	95% CI
Mindful After Cancer	0.06	-0.87 – 0.98

Change From Baseline Body Image at 1 Month Secondary · Baseline (T1) and 1 month post-intervention (T2)

Body Image Scale. 10 items. Range 0-30. Higher score indicates poorer body image.

T1 Mean, SD

Group	Value	95% CI
Mindful After Cancer	15.2	± 7.1

T2 Mean, SD

Group	Value	95% CI
Mindful After Cancer	13.1	± 8.2

Change From Baseline Body Appreciation at 1 Month Secondary · Baseline (T1) and 1 month post-intervention (T2)

Body Appreciation Scale. 13 items. Range 13-65. Higher score indicates more positive body appreciation.

T1 Mean, SD

Group	Value	95% CI
Mindful After Cancer	3.2	± 0.7

T2 Mean, SD

Group	Value	95% CI
Mindful After Cancer	3.6	± 0.7

Change From Baseline Anxiety at 1 Month Secondary · Baseline (T1) and 1 month post-intervention (T2)

PROMIS Emotional Distress Anxiety Short Form 6a. 6 items. Range 6-30. Higher score indicates greater anxiety symptoms.

T1 Mean, SD

Group	Value	95% CI
Mindful After Cancer	15.0	± 5.4

T2 Mean, SD

Group	Value	95% CI
Mindful After Cancer	12.9	± 4.4

Change From Baseline Depression at 1 Month Secondary · Baseline (T1) and 1 month post-intervention (T2)

Center for Epidemiologic Studies Depression Scale (CES-D). 20 items. Range 0-60. Higher score indicates greater depressive symptoms

T1 Mean, SD

Group	Value	95% CI
Mindful After Cancer	16.3	± 9.0

T2 Mean, SD

Group	Value	95% CI
Mindful After Cancer	13.9	± 11.3

Change in Facets of Baseline Mindfulness at 1 Month Secondary · Baseline (T1) and 1 month post-intervention (T2)

Five-Facet Mindfulness Questionnaire (FFMQ-15). 15 items with 5 sub-scales: Observe, Describe; Act with Awareness; Non-Judgement, Non-Reactivity. Sub-scale score range 3-15. Higher score indicates greater mindfulness.

Observe subscale T1 Mean, SD

Group	Value	95% CI
Mindful After Cancer	10.8	± 2.1

Observe subscale T2 Mean, SD

Group	Value	95% CI
Mindful After Cancer	9.6	± 0.9

Acting with Awareness subscale T1 Mean, SD

Group	Value	95% CI
Mindful After Cancer	9.3	± 2.0

Acting with Awareness subscale T2 Mean, SD

Group	Value	95% CI
Mindful After Cancer	10.8	± 2.2

Non-reactivity subscale T1 Mean, SD

Group	Value	95% CI
Mindful After Cancer	9.7	± 2.4

Non-reactivity subscale T2 Mean, SD

Group	Value	95% CI
Mindful After Cancer	8.9	± 1.0

Non-judging subscale T1 Mean, SD

Group	Value	95% CI
Mindful After Cancer	10.7	± 2.4

Non-judging subscale T2 Mean, SD

Group	Value	95% CI
Mindful After Cancer	8.8	± 1.4

Sponsor's own description

The objectives of this study are to: 1) adapt a mindfulness-based therapy program designed to help women manage their sexual and body image concerns after cancer (Mindful After Cancer, MAC) to a videoconference format and 2) assess the feasibility, acceptability, and preliminary effects of the program among breast and gynecologic cancer survivors.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.